Objectives: Non-fermentative Gram-negative bacilli (non-fermenters) can cause serious healthcare-associated infections and are often resistant to multiple antibiotics. We examined resistance rates among these bacteria from different regions of Saudi Arabia.
Introduction
Non-fermentative Gram-negative bacilli (non-fermenters) account for ≥15% of isolates examined in most clinical microbiology laboratories. 1 The predominant species of concern are Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and, less so, members of the Burkholderia cepacia group. 2 These organisms are generally saprophytic, but cause opportunistic infections in seriously ill, hospitalized and immunocompromised patients. 3 They are particularly associated with urinary tract infections, ventilator pneumonia, surgical site infections and bacteraemias.
3 P. aeruginosa and A. baumannii account for .10% of hospital-acquired infections in American intensive care units (ICUs). 4 Non-fermenters often are multidrug resistant, with resistance increasing to oxyimino-cephalosporins and carbapenems over the last two decades.
2, 5 Resistance may compromise treatment, leading to increased mortality, extended hospital stay and greater healthcare costs. 6 Several local studies have examined the prevalence of resistance among non-fermenters in Saudi Arabia, but none was comprehensive, and comparisons are complicated by variable methods and study periods. 7, 8 The aim of this study was to examine resistance rates among non-fermenters from different geographical regions of Saudi Arabia during a single year, using a standardized method.
Methods

Population
The study examined clinical non-fermenters obtained at 24 Saudi Ministry of Health hospitals distributed in six administrative regions: Riyadh, Jeddah, Makkah, Eastern Region, Hail and Asir. These represent the central, western, eastern, northern and southern geographical regions, with three to five hospitals per region (Figure 1 ). The hospitals were tertiary centres, with 100-1100 beds (average 378); intensive care beds comprised 1.0%-12.2% of these totals (average 4.2%).
Study design
The study had a cross-sectional design and was conducted between January and December 2009. Clinical P. aeruginosa, A. baumannii and S. maltophilia were surveyed from blood, urine, wound swabs, sputum, and other body sites and fluids, irrespective of whether they came from in-or outpatients and from ICU-and non-ICU patients.
Laboratory methods
Susceptibility testing was performed at the source hospitals by disc diffusion, following the guidelines of the CLSI. 8 To ensure data compatibility, quality control was performed using control strains from the ATCC as follows: Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853 and Klebsiella pneumoniae ATCC 27736. The study coordinators made several visits to the testing laboratories to ensure that the CLSI guidelines were strictly followed, and that the quality control tests were performed weekly and with each new batch of test isolates. The antimicrobial agents included were those routinely tested by the participating laboratories and varied among the sites.
Data analysis
Differences in resistance rates between administrative regions were compared using 
Results
Isolates and patterns of testing
In total, 8908 non-fermenters were examined (Table 1) . Most were P. aeruginosa (n¼ 6497, 72.9%), followed by A. baumannii (n¼ 2252, 25.3%) and S. maltophilia (n ¼159, 1.8%). These isolates were obtained in Riyadh (n ¼3300, 37.0%), Jeddah (n¼ 1465, 16.4%), Makkah (n ¼1401, 15.7%), Eastern Region (n¼ 998, 11.2%), Asir (n¼ 922, 10.4%) and Hail (n¼ 822, 9.2%). Over 90% of the isolates were tested with amikacin, imipenem, gentamicin and chloramphenicol, drugs relevant to some or all of the species reviewed, and tetracycline was tested against half the isolates. A few isolates were tested with other highly relevant antibiotics, including ceftazidime (30.2%), polymyxin B (20.6%), piperacillin/tazobactam (12.2%), tobramycin or netilmicin (both 9.2%), whereas surprisingly large proportions were tested with antibiotics unlikely to be active against clinical non-fermenters, including ceftriaxone (83.4% tested), erythromycin (39.3%) and cefotaxime (37.0%). Fewer than half the S. maltophilia isolates were tested with trimethoprim/sulfamethoxazole, the standard treatment for infections due to this species. Memish et al.
Resistance rates
Less than 20% of P. aeruginosa isolates tested were resistant to imipenem or-among the small minorities tested-to piperacillin/tazobactam, polymyxins or ceftazidime (Table 1) , whilst 20% -32% were resistant to ciprofloxacin, amikacin and gentamicin. Among A. baumannii isolates, resistance rates of .50% were recorded for all relevant antibiotics except imipenem (5.4%) and polymyxin B (13.2%), with the caveat that polymyxin B was only tested against a small minority of isolates. Most S. maltophilia isolates were predictably resistant to most of the antibiotics tested. Surprisingly, 20.5% were resistant even to trimethoprim/sulfamethoxazole, whilst more-among the minority testedappeared susceptible to polymyxin B (6.9% resistance).
Regional variation
The antimicrobial resistance rates varied across the geographical regions (Table 2) . Imipenem resistance in A. baumannii was significantly (P,0.001) more prevalent in Eastern Region (13.1%) than elsewhere (2.6% -5.3%) and, for P. aeruginosa, was significantly (P,0.001) less prevalent in Hail (2.9%) than elsewhere (13.9% -21.2%). An apparently lower imipenem resistance among S. maltophilia in Jeddah (59.5% versus 90.9%-100% elsewhere, P,0.001) may point to a testing issue, in view of the intrinsic resistance of the species to this drug.
Discussion
We surveyed the susceptibility of the three major non-fermenters across all geographical regions of Saudi Arabia. The numbers of isolates (n¼ 8908) and participating hospitals (n¼ 24) greatly exceeded previous studies of non-fermenters in Saudi Arabia, which were based on small numbers of isolates from one to four hospitals each, with significant potential for distortion by local outbreak strains. 6, 7, 9 Moreover, we sought to ensure adoption of standardized methodology.
The resistance rates found here were mostly at the lower end of the extremely wide ranges reported by these previous small investigations; 6, 7, 9 they were comparable to some large-scale US studies and lower than those in many other developing countries. 5, 10 It is particularly noteworthy that the imipenem resistance rate in A. baumannii here was comparable to that reported in the USA, but lower than in much of Europe and in many developing countries (5.4% versus 7%-25% and 44%, respectively). 6 On the other hand, the rate of trimethoprim/ sulfamethoxazole resistance in S. maltophilia was higher than in both Western and developing countries (20.5% versus 2%-10%).
3
The survey indicated significant variations in resistance rates across the administrative regions of Saudi Arabia, though the magnitude of these was generally smaller than implied by comparing previous studies for small numbers of hospitals in individual regions. 6, 7, 9 It should, however, be cautioned that the numbers of isolates of A. baumannii and S. maltophilia were small in some regions. Moreover, all rates are subject to change over time and a recent report from Riyadh showed that many Gram-negative bacilli, including A. baumannii, had gained increasing antimicrobial resistance during a 6 year period (e.g. with a local doubling of imipenem resistance from 45% to 90%). 6 Although the study has the advantage of size and wide geographical coverage, limitations remain. Not all the hospitals tested the same antibiotics and, more seriously, many highly relevant antibiotics were tested in only a few hospitals. Critical examples include ceftazidime, piperacillin/tazobactam and tobramycin, which, respectively, are the most active cephalosporin, penicillin and aminoglycoside against P. aeruginosa and yet were tested against only 10% -33% of the isolates. Likewise, Resistance among non-fermenters in Saudi Arabia polymyxins were tested against only 27% of the P. aeruginosa isolates. In contrast, drugs of little relevance were widely tested, including erythromycin, chloramphenicol and tetracycline (which all lack activity against P. aeruginosa) as well as ceftriaxone, which has marginal activity, at best, against nonfermenters. MastRings were commonly used, leading to bacteria being tested with set batteries of agents. These are limitations, as is the lack of data on the types of specimens and hospital care for the source patients. Nevertheless, we believe that these findings serve as a local benchmarking (i) to guide empirical antimicrobial prescribing and (ii) to encourage the testing of more appropriate antibiotics against these clinically important species. This is important because in Saudi Arabia, as elsewhere, we are seeing high rates of antimicrobial resistance among nonfermenters; moreover, separate data for Riyadh (A. M. Shibl, unpublished data) show that some of the resistance in P. aeruginosa is due to potent VIM, VEB and GES b-lactamases, sometimes produced by outbreak strains. Efforts are urgently required to preserve the efficacy of the few medications that are active against non-fermenters.
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